

**APA099Ra61 100µg**

**Active Matrix Metalloproteinase 13 (MMP13)**

**Organism Species: Rattus norvegicus (Rat)**

***Instruction manual***

FOR IN VITRO USE AND RESEARCH USE ONLY  
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

---

---

1th Edition (Apr, 2016)

## **[ PROPERTIES ]**

**Source:** Eukaryotic expression.

**Host:** 293F cell

**Residues:** Leu14~Cys466

**Tags:** N-terminal His-tag

**Purity:** >98%

**Buffer Formulation:** 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 0.01% sarcosyl and 5%Trehalose.

**Applications:** Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

**Predicted isoelectric point:** 5.1

**Predicted Molecular Mass:** 53.4kDa

**Accurate Molecular Mass:** 60kDa as determined by SDS-PAGE reducing conditions.

**Phenomenon explanation:**

The possible reasons that the actual band size differs from the predicted are as follows:

1. Splice variants: Alternative splicing may create different sized proteins from the same gene.
2. Relative charge: The composition of amino acids may affects the charge of the protein.
3. Post-translational modification: Phosphorylation, glycosylation, methylation etc.
4. Post-translation cleavage: Many proteins are synthesized as pro-proteins, and then cleaved to give the active form.
5. Polymerization of the target protein: Dimerization, multimerization etc.

## **[ USAGE ]**

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

## **[ STORAGE AND STABILITY ]**

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.


## **[ SEQUENCE ]**

```
LPLPYGD DDDDDLSEED LEFAEHYLKS YYHPVTLAGI
LKKSTVTSTV DRLREMQSFF GLDVTGKLDD PTLDIMRKPR CGVPDVGVYN
VFPRTLKWSQ TNLYRIVNY TPDISHSEVE KAFRKAFKVV SDVTPLNFTR
IHDGTADIMI SFGTKEHGDF YPFDGPGSLL AHAFPPGNL GGDAHFDDE
TWTSSSKGYN LFIVAAHELH HSLGLDHSKD PGALMFPIYT YTGKSHFMLP
DDDVGQIQSL YGPGDEDPNP KHPKTPEKCD PALSldaITS LRGETMIFKD
RFFWRLHPQQ VEPELFLTKS FWPELPHVD AAYEHPSRDL MFIFRGRKFW
ALNGYDIMEG YPRKISDLGF PKEVKRLSAA VHFEDTGKTL FFSGNHVWSY
DDANQTMKD YPRLIEEEFP GIGDKVDVAVY EKNGYIYFFN GPIQFEYSIW
SNRIVRVMP NSLLWC
```

## **[ ACTIVITY ]**


Matrix Metalloproteinase 13 (MMP13) is a member of the matrix metalloproteinase (MMP) family. MMP13 has been proposed to participate in aggrecan degradation associated with osteoarthritis and cleavage of type II collagen in osteoarthritic cartilage explants and in tumor progression and metastasis. In addition, it can cleave type I, III, IV, IX, X and XIV collagens and fibronectin. MMP13 is likely to





**Figure 3. SDS-PAGE**

**Sample: Active recombinant MMP13, Rat**



**Figure 4. Western Blot**

**Sample: Recombinant MMP13, Rat;**

**Antibody: Rabbit Anti-Rat MMP13 Ab (PAA099Ra06)**